UBS Group’s Trinity Biotech TRIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $546 | Buy |
1,007
+227
| +29% | +$167 | ﹤0.01% | 9837 |
|
|
2025
Q4 | $617 | Buy |
780
+729
| +1,429% | +$717 | ﹤0.01% | 9874 |
|
|
2025
Q3 | $53 | Buy |
+51
| New | +$54 | ﹤0.01% | 10013 |
|
|
2025
Q1 | – | Sell |
-10,621
| Closed | -$9.35K | – | 10734 |
|
|
2024
Q4 | $9.35K | Buy |
+10,621
| New | +$14.2K | ﹤0.01% | 8364 |
|
|
2024
Q2 | – | Sell |
-5,178
| Closed | -$10.6K | – | 10096 |
|
|
2024
Q1 | $10.6K | Buy |
5,178
+5,175
| +172,500% | +$12.1K | ﹤0.01% | 7222 |
|
|
2023
Q4 | $7 | Sell |
3
-25
| -89% | -$60 | ﹤0.01% | 9143 |
|
|
2023
Q3 | $104 | Buy |
+28
| New | +$115 | ﹤0.01% | 8876 |
|
|
2023
Q2 | – | Sell |
-2,418
| Closed | -$11.4K | – | 9662 |
|
|
2023
Q1 | $11.4K | Buy |
2,418
+2,324
| +2,472% | +$12K | ﹤0.01% | 7510 |
|
|
2022
Q4 | $466 | Sell |
94
-1,800
| -95% | -$10.9K | ﹤0.01% | 10172 |
|
|
2022
Q3 | $10K | Buy |
+1,894
| New | +$12.2K | ﹤0.01% | 8458 |
|
|
2022
Q2 | – | Sell |
-140
| Closed | -$1K | – | 10950 |
|
|
2022
Q1 | $1K | Sell |
140
-1,146
| -89% | -$6.6K | ﹤0.01% | 9932 |
|
|
2021
Q4 | $9K | Buy |
1,286
+1,165
| +963% | +$11K | ﹤0.01% | 8927 |
|
|
2021
Q3 | $1K | Sell |
121
-516
| -81% | -$6.05K | ﹤0.01% | 9247 |
|
|
2021
Q2 | $9K | Buy |
637
+526
| +474% | +$8.75K | ﹤0.01% | 8162 |
|
|
2021
Q1 | $2K | Sell |
111
-146
| -57% | -$3.51K | ﹤0.01% | 8645 |
|
|
2020
Q4 | $5K | Buy |
+257
| New | +$4.25K | ﹤0.01% | 7848 |
|
|
2020
Q2 | – | Sell |
-3,029
| Closed | -$17K | – | 8359 |
|
|
2020
Q1 | $17K | Buy |
3,029
+2,200
| +265% | +$11.5K | ﹤0.01% | 6597 |
|
|
2019
Q4 | $4K | Buy |
+829
| New | +$3.94K | ﹤0.01% | 7683 |
|
|
2019
Q3 | – | Sell |
-82
| Closed | -$1K | – | 8258 |
|
|
2019
Q2 | $1K | Buy |
+82
| New | +$975 | ﹤0.01% | 7737 |
|
|
2018
Q4 | – | Sell |
-113
| Closed | -$2K | – | 8296 |
|
|
2018
Q3 | $2K | Buy |
+113
| New | +$2.46K | ﹤0.01% | 7755 |
|
|
2018
Q2 | – | Sell |
-229
| Closed | -$6K | – | 8246 |
|
|
2018
Q1 | $6K | Buy |
229
+175
| +324% | +$4.77K | ﹤0.01% | 7162 |
|
|
2017
Q4 | $1K | Buy |
+54
| New | +$1.39K | ﹤0.01% | 7729 |
|
|
2017
Q2 | – | Sell |
-427
| Closed | -$13K | – | 7987 |
|
|
2017
Q1 | $13K | Buy |
427
+273
| +177% | +$8.54K | ﹤0.01% | 6463 |
|
|
2016
Q4 | $5K | Buy |
+154
| New | +$5.3K | ﹤0.01% | 7257 |
|
|
2016
Q3 | – | Sell |
-122
| Closed | -$7K | – | 7937 |
|
|
2016
Q2 | $7K | Sell |
122
-342
| -74% | -$19.3K | ﹤0.01% | 6989 |
|
|
2016
Q1 | $28K | Buy |
464
+404
| +673% | +$21.4K | ﹤0.01% | 5947 |
|
|
2015
Q4 | $4K | Sell |
60
-273
| -82% | -$16.1K | ﹤0.01% | 7792 |
|
|
2015
Q3 | $19K | Buy |
333
+193
| +138% | +$15.5K | ﹤0.01% | 6752 |
|
|
2015
Q2 | $13K | Sell |
140
-392
| -74% | -$33.9K | ﹤0.01% | 7268 |
|
|
2015
Q1 | $51K | Sell |
532
-188
| -26% | -$17.4K | ﹤0.01% | 6026 |
|
|
2014
Q4 | $63K | Buy |
+720
| New | +$62K | ﹤0.01% | 6206 |
|
Other funds holding TRIB
HAIM
YAG
WN
VF
MAWA
IWA
BCM
UBS Group's TRIB Position: Q1 2026 in Review
UBS Group increased its Trinity Biotech (TRIB) stake by 29% in Q1 2026, buying an estimated $167 and bringing the position to 1,007 shares worth $546. The position accounts for ﹤0.01% of the portfolio, ranked #9837.
UBS Group first reported a position in TRIB in Q4 2014 and has held it in 31 quarters since. The position peaked at $63K in Q4 2014. 23 funds tracked by Wall St. Rank hold TRIB as of Q1 2026.
- UBS Group held 1,007 shares of Trinity Biotech worth $546 as of Q1 2026.
- UBS Group bought 227 Trinity Biotech shares in Q1 2026, an estimated $167.
- Trinity Biotech made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9837 holding.
- UBS Group first reported a position in Trinity Biotech in Q4 2014 and has held it in 31 quarters since.
- UBS Group's Trinity Biotech position peaked at $63K in Q4 2014.
- 23 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.